Scientist | Target Discovery & Validation | Ophthalmology Research | AAV Gene Therapy | RNA-based Therapy | Cell Therapy | Assay Development | iPSC | CRISPR | Oncology | Hearing Loss | CRO | Cricketer
Exciting work! Researchers have identified that alterations in AKT2 disrupt lysosome function in the retina, leading to drusen deposits, a hallmark of dry AMD (non-neovascular). This dysfunction, observed in both patient iPSC-derived RPE cells and mice models, results in RPE degeneration and drusen formation. ***The findings suggest that targeting the AKT2/SIRT5/TFEB pathway could be a potential therapy for dry AMD, a major cause of vision loss in the United States***. Worth reading: https://lnkd.in/ejdh4PUs
NIH researchers discover potential target for "dry" age-related macular degeneration (AMD). National Institutes of Health (NIH): Intramural Research Program (IRP) scientists Kapil Bharti and Ruchi Sharma and collaborators at Johns Hopkins Medicine detailed how lysosomal dysfunction results in drusen via AKT2. https://go.nih.gov/Ojvlu0C
